Cargando…

Critically ill patients with edema and ascites may experience subtherapeutic anti-factor Xa levels following abdominal subcutaneous enoxaparin treatment

Enoxaparin is a low molecular weight heparin that is principally prescribed for the treatment and prevention of thromboembolic disorders. In clinical practice, the abdominal site for subcutaneous enoxaparin administration is most preferable because of its simplicity and safety. However, subcutaneous...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tharanon, Vichapat, Kawamatawong, Theerasuk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393492/ https://www.ncbi.nlm.nih.gov/pubmed/36003894 http://dx.doi.org/10.1177/2050313X221118200

Ejemplares similares

Use of anti-Xa factor titration as efficacy marker of enoxaparin in critically ill patients
por: Lage, S, et al.
Publicado: (2006)

Standard- versus intermediate-dose enoxaparin for anti-factor Xa guided thromboprophylaxis in critically ill patients with COVID-19
por: Hamilton, David Oliver, et al.
Publicado: (2021)

Antifactor Xa Levels in Critically Ill Korean Patients Receiving Enoxaparin for Thromboprophylaxis: A Prospective Observational Study
por: Lim, So Yeon, et al.
Publicado: (2013)

Phosphodiesterase-4 Inhibitors for Non-COPD Respiratory Diseases
por: Kawamatawong, Theerasuk
Publicado: (2021)

Prophylactic anticoagulation with low dose enoxaparin: is the subcutaneous route appropriate in the critically ill?
por: Priglinger, U, et al.
Publicado: (2002)

Anti-factor Xa Activity Is Not Associated With Venous Thromboembolism in Critically Ill Patients Receiving Enoxaparin for Thromboprophylaxis: A Retrospective Observational Study
por: Dibiasi, Christoph, et al.
Publicado: (2022)

Drug-related problems identified during pharmaceutical care interventions in an intensive care unit at a tertiary university hospital
por: Tharanon, Vichapat, et al.
Publicado: (2022)

Anti-factor Xa levels in obese patients receiving enoxaparin for treatment and prophylaxis indications
por: Tahaineh, Linda, et al.
Publicado: (2018)

742 Evaluation of Anti-Xa Levels and Venous Thromboembolism Prophylaxis with Enoxaparin in Burn Patients
por: Boyd, Allison, et al.
Publicado: (2023)

Vancomycin levels are frequently subtherapeutic in critically ill patients: a prospective observational study
por: Bakke, V., et al.
Publicado: (2017)

Role of eosinophilic inflammation and atopy in elderly asthmatic patients
por: Kawamatawong, Theerasuk, et al.
Publicado: (2016)

Erratum: Correction of Figure 1: The asthma and chronic obstructive pulmonary disease overlap syndrome in tertiary care setting Thailand
por: Kawamatawong, Theerasuk, et al.
Publicado: (2018)

The asthma and chronic obstructive pulmonary disease overlap syndrome in tertiary care setting Thailand
por: Kawamatawong, Theerasuk, et al.
Publicado: (2017)

Relationship between the presence of bronchiectasis and acute exacerbation in Thai COPD patients
por: Kawamatawong, Theerasuk, et al.
Publicado: (2018)

Peak inspiratory flow rate measurement by using In-Check DIAL for the different inhaler devices in elderly with obstructive airway diseases
por: Kawamatawong, Theerasuk, et al.
Publicado: (2017)

Serum inflammatory biomarkers and clinical outcomes of COPD exacerbation caused by different pathogens
por: Kawamatawong, Theerasuk, et al.
Publicado: (2017)

Anti-activated factor × response to enoxaparin in critically ill patients
por: Einav, S, et al.
Publicado: (2009)

Preliminary report of an enoxaparin dose protocol based on anti-Xa activity in continuous renal replacement therapy
por: Costa, JLF, et al.
Publicado: (2007)

Supratherapeutic anti-factor Xa levels in patients receiving prophylactic doses of enoxaparin: A case series
por: Pannucci, Christopher J., et al.
Publicado: (2016)

Assessment of anti-factor Xa activity of enoxaparin for venous thromboembolism prophylaxis in morbidly obese surgical patients
por: Al Otaib, Nouf, et al.
Publicado: (2017)

Value of venous thromboembolism prophylaxis by enoxaparin with anti-factor Xa trough concentration monitoring in surgical care
por: Zachariah, Seeba, et al.
Publicado: (2020)

Comparison of Anti-factor Xa Levels in Female and Male Patients with Obesity After Enoxaparin Application for Thromboprophylaxis
por: Wagner, Jonas, et al.
Publicado: (2022)

Vancomycin for Dialytic Therapy in Critically Ill Patients: Analysis of Its Reduction and the Factors Associated with Subtherapeutic Concentrations
por: de Freitas, Fernanda Moreira, et al.
Publicado: (2020)

Pharmacokinetics of enoxaparin in COVID-19 critically ill patients
por: Zufferey, Paul Jacques, et al.
Publicado: (2021)

Subcutaneous edema as rare complication of abdominal paracentesis
por: Otsuka, Yuki, et al.
Publicado: (2021)

Anti-Xa Directed Thromboprophylaxis in Critically Ill Patients with Coronavirus Disease 2019
por: Mohamed, Adham, et al.
Publicado: (2022)

Optimal Dosing of Enoxaparin in Critically Ill Patients with Venous Thromboembolism
por: Abdulla, Aliya, et al.
Publicado: (2023)

Anti-Xa Activity of Enoxaparin for Prevention of Venous Thromboembolism in Severe Nephrotic Syndrome—A Single Center Prospective Study
por: Matyjek, Anna, et al.
Publicado: (2021)

Increased dosing regimens of piperacillin-tazobactam are needed to avoid subtherapeutic exposure in critically ill patients with augmented renal clearance
por: Besnard, Thibaud, et al.
Publicado: (2019)

Factor Xa Levels in Patients Receiving Prophylactic Enoxaparin Sodium in the Intensive Care Unit of an Academic Hospital
por: Baloo, Mayank M, et al.
Publicado: (2021)

Clinical experience of prophylactic enoxaparin dosage adjustment guided by AntiXa factor levels in critical care patients with COVID-19-induced pneumonia: observational study()
por: Bermúdez-Ruiz, María del Carmen, et al.
Publicado: (2023)

Effects of dalteparin on anti‐Xa activities cannot be predicted in critically ill COVID‐19 patients
por: van der Heijden, Charlotte D. C. C., et al.
Publicado: (2022)

The right time to measure anti-Xa activity in critical illness: pharmacokinetics of therapeutic dose nadroparin
por: Sytema, Jelmer G., et al.
Publicado: (2023)

Major vessel occlusion may predict subtherapeutic anticoagulation intensity and feasibility of administration of intravenous thrombolytics
por: Chang, Jun Young, et al.
Publicado: (2017)

Acute Cardioembolic Stroke in the Setting of Subtherapeutic Anticoagulation
por: Ambatipudi, Ankit, et al.
Publicado: (2023)

Anti-Xa activity after subcutaneous administration of dalteparin in intensive care unit patients with and without subcutaneous oedema
por: Rommers, M, et al.
Publicado: (2005)

Anti-Factor Xa Levels in Low-weight Surgical Patients Receiving Enoxaparin for Venous Thromboembolism Prophylaxis: A Prospective Cohort Study
por: Hakeam, Hakeam A., et al.
Publicado: (2020)

Efficacy and safety of enoxaparin as deep vein thrombosis prophylaxis in critically ill patients
por: Al-Hubail, R, et al.
Publicado: (2012)

The effect of a new direct Factor Xa inhibitor on human osteoblasts: an in-vitro study comparing the effect of rivaroxaban with enoxaparin
por: Solayar, Gandhi N, et al.
Publicado: (2011)

An in vitro study to investigate the interference of enoxaparin on plasma levels of direct oral factor Xa inhibitors measured by chromogenic assays
por: Cini, Michela, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_d621sslp37l7e8iholqitc16kq